The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban‐treated patients: results of an in vitro study
- 13 October 2010
- journal article
- letter
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9 (1), 226-228
- https://doi.org/10.1111/j.1538-7836.2010.04106.x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Reporting prothrombin time results as international normalized ratios for patients with chronic liver diseaseJournal of Thrombosis and Haemostasis, 2010
- Application of the international normalized ratio in the scoring system for disseminated intravascular coagulationJournal of Thrombosis and Haemostasis, 2010
- New oral antithrombotics: a need for laboratory monitoring. ForJournal of Thrombosis and Haemostasis, 2010
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 2008
- Thromboplastin Composition Affects the Sensitivity of Prothrombin Time (PT) Clotting Tests To Direct Factor Xa Inhibitors.Blood, 2007
- Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determinationJournal of Thrombosis and Haemostasis, 2004